Piper Sandler raised the firm’s price target on Halozyme (HALO) to $53 from $52 and keeps a Neutral rating on the shares after maintaining FY24 guidance and providing its FY25 outlook. The primary driver of this guidance looks to be greater visibility in wave three launches/conversion rates, with Vyvgart the primary contributor in 2025 and the others having more meaningful impact in 2026, according to Piper. The firm added that 2025 guidance looks “wholly reasonable.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme price target raised to $70 from $68 at H.C. Wainwright
- Exxon and Shell cautious on Q4, Flutter cuts guidance: Morning Buzz
- Halozyme raises FY25 adjusted EPS view to $4.95-$5.35 from $4.45-$4.85
- Halozyme announces new $250M accelerated share repurchase plan
- Halozyme backs FY24 adjusted EPS view $4.00-$4.20, consensus $4.14